An Open Label, Dose-Escalation Study to Evaluate Safety, Tolerability, Maximum Tolerated Dose (MTD), Efficacy, and Pharmacokinetics (PKs) of CPI-613 Given Twice Weekly for Three Consecutive Weeks in Patients With Advanced Hematologic Malignancies.

Trial Profile

An Open Label, Dose-Escalation Study to Evaluate Safety, Tolerability, Maximum Tolerated Dose (MTD), Efficacy, and Pharmacokinetics (PKs) of CPI-613 Given Twice Weekly for Three Consecutive Weeks in Patients With Advanced Hematologic Malignancies.

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Jun 2017

At a glance

  • Drugs CPI 613 (Primary)
  • Indications Acute myeloid leukaemia; Burkitt's lymphoma; Cutaneous T cell lymphoma; Haematological malignancies; Myelodysplastic syndromes
  • Focus Adverse reactions
  • Most Recent Events

    • 07 Oct 2014 According to a Cornerstone Pharmaceuticals media release, data was published in Clinical Cancer Research: the official journal of the AACR 2014 and presented at the 2013 American Society of Clinical Oncology (ASCO) Annual Meeting.
    • 10 Dec 2013 Results presented at the 55th Annual Meeting and Exposition of the American Society of Hematology.
    • 25 Sep 2013 Status changed from active, no longer recruiting to completed, according to a Cornerstone Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top